147.64
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché KRYS Giù?
Forum
Previsione
Precedente Chiudi:
$146.88
Aprire:
$146.04
Volume 24 ore:
163.42K
Relative Volume:
0.46
Capitalizzazione di mercato:
$4.27B
Reddito:
$290.51M
Utile/perdita netta:
$89.16M
Rapporto P/E:
49.38
EPS:
2.99
Flusso di cassa netto:
$119.18M
1 W Prestazione:
+1.22%
1M Prestazione:
+0.02%
6M Prestazione:
-14.83%
1 anno Prestazione:
-25.52%
Krystal Biotech Inc Stock (KRYS) Company Profile
Nome
Krystal Biotech Inc
Settore
Industria
Telefono
(412) 586-5830
Indirizzo
2100 WHARTON STREET, PITTSBURGH, PA
Confronta KRYS con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
KRYS
Krystal Biotech Inc
|
147.64 | 4.25B | 290.51M | 89.16M | 119.18M | 2.99 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
389.08 | 99.27B | 11.39B | 3.64B | 3.50B | 13.99 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
586.96 | 62.28B | 14.21B | 4.46B | 3.56B | 39.68 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
454.18 | 59.14B | 2.46B | -319.09M | -52.09M | -2.47 |
![]()
ARGX
Argen X Se Adr
|
707.96 | 43.34B | 3.06B | 1.28B | 447.35M | 21.30 |
![]()
ONC
Beone Medicines Ltd Adr
|
300.14 | 36.72B | 3.81B | -644.79M | -669.77M | -6.24 |
Krystal Biotech Inc Stock (KRYS) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2025-03-05 | Iniziato | Jefferies | Buy |
2024-08-06 | Downgrade | Citigroup | Buy → Neutral |
2023-11-20 | Iniziato | Goldman | Buy |
2023-10-24 | Iniziato | Cantor Fitzgerald | Overweight |
2023-10-12 | Iniziato | Citigroup | Buy |
2023-09-07 | Iniziato | Berenberg | Buy |
2023-04-18 | Iniziato | Stifel | Buy |
2023-02-28 | Aggiornamento | Goldman | Neutral → Buy |
2022-08-25 | Downgrade | Goldman | Buy → Neutral |
2022-01-18 | Iniziato | BofA Securities | Buy |
2021-07-20 | Aggiornamento | Goldman | Neutral → Buy |
2020-09-18 | Iniziato | B. Riley FBR | Buy |
2020-06-04 | Iniziato | Evercore ISI | Outperform |
2019-09-24 | Iniziato | Goldman | Neutral |
2019-08-06 | Reiterato | H.C. Wainwright | Buy |
2019-06-24 | Reiterato | Chardan Capital Markets | Buy |
2019-06-24 | Reiterato | H.C. Wainwright | Buy |
2019-05-30 | Iniziato | Guggenheim | Buy |
2018-09-11 | Iniziato | Cantor Fitzgerald | Overweight |
Mostra tutto
Krystal Biotech Inc Borsa (KRYS) Ultime notizie
Will Krystal Biotech Inc. price bounce be sustainableQuarterly Performance Summary & Fast Moving Trade Plans - Newser
Analyzing net buyer seller activity in Krystal Biotech Inc.Portfolio Value Report & Stepwise Swing Trade Plans - Newser
Using data models to predict Krystal Biotech Inc. stock movement2025 Historical Comparison & Reliable Intraday Trade Plans - Newser
Order flow analysis tools used on Krystal Biotech Inc.Gap Down & AI Powered Trade Plan Recommendations - Newser
Using flow based indicators on Krystal Biotech Inc.2025 Key Lessons & Free Verified High Yield Trade Plans - Newser
What MACD and RSI say about Krystal Biotech Inc.Weekly Trade Report & Community Shared Stock Ideas - Newser
How to track smart money flows in Krystal Biotech Inc.2025 Market Trends & Weekly Consistent Profit Watchlists - Newser
Quantitative breakdown of Krystal Biotech Inc. recent moveEarnings Summary Report & Free Weekly Chart Analysis and Trade Guides - Newser
Is this a good reentry point in Krystal Biotech Inc.Market Performance Summary & Safe Entry Trade Signal Reports - Newser
Should you wait for a breakout in Krystal Biotech Inc.Market Sentiment Summary & Verified Technical Trade Signals - Newser
Will Krystal Biotech Inc. stock recover after recent dropWeekly Gains Report & Consistent Profit Alerts - Newser
Combining machine learning predictions for Krystal Biotech Inc.IPO Watch & Risk Managed Investment Strategies - Newser
Krystal Biotech Inc. stock retracement – recovery analysisOil Prices & Reliable Entry Point Trade Alerts - Newser
Has Krystal Biotech Inc. found a price floor2025 Volume Leaders & Intraday High Probability Setup Alerts - Newser
Ranking Krystal Biotech Inc. among high performing stocks via toolsTake Profit & Reliable Price Action Trade Plans - Newser
Understanding Krystal Biotech Inc.’s price movement2025 Earnings Surprises & Stepwise Trade Signal Guides - Newser
Using data filters to optimize entry into Krystal Biotech Inc.Trade Analysis Report & Verified Chart Pattern Trade Signals - Newser
Is Krystal Biotech Inc. stock poised for growthWeekly Trade Summary & Weekly Hot Stock Watchlists - Newser
How to monitor Krystal Biotech Inc. with trend dashboardsAnalyst Downgrade & Stepwise Entry and Exit Trade Signals - Newser
How to use Fibonacci retracement on Krystal Biotech Inc.Weekly Stock Report & High Yield Stock Recommendations - Newser
Key metrics from Krystal Biotech Inc.’s quarterly data2025 Institutional Moves & Real-Time Stock Movement Alerts - Newser
Published on: 2025-08-25 22:18:19 - Newser
Krystal Biotech Inc. Building a Base Near SupportWeekly Loss Report & Expert Approved Trade Ideas - kangso.co.kr
Building trade automation scripts for Krystal Biotech Inc.July 2025 Trends & Weekly Market Pulse Alerts - Newser
Support Zone Holds Steady for Krystal Biotech Inc. After DipJuly 2025 PostEarnings & Short-Term Trading Alerts - beatles.ru
Is Krystal Biotech Inc. stock undervalued right nowWeekly Trend Summary & Breakout Confirmation Alerts - theviewers.co.kr
Krystal Biotech adjusts pipeline to prioritize inhaled antitumor agent - MSN
Krystal Biotech shares rise 3.58% intraday after Chardan trims price target to $216. - AInvest
Krystal Biotech: A "Strong Buy" Despite KB707 Melanoma Tumor Targeting Update (KRYS) - Seeking Alpha
Chardan Trims Price Target on Krystal Biotech to $216 From $219, Keeps Buy Rating - MarketScreener
What is the earnings history of Krystal Biotech Inc.July 2025 Pullbacks & Smart Allocation Stock Reports - theviewers.co.kr
Krystal Biotech Inc. Nearing Breakout Level After BounceJuly 2025 Momentum & High Conviction Buy Zone Alerts - 더경남뉴스
Krystal Biotech prioritizes inhaled cancer drug (KRYS:NASDAQ) - Seeking Alpha
Krystal Biotech to Prioritize Inhaled KB707 for Treatment of Non-Small Cell Lung Cancer - MarketScreener
Krystal Biotech granted FDA meeting for KB707 for October - MarketScreener
Krystal Biotech advances lung cancer therapy to FDA discussions - Investing.com
Krystal Biotech Provides Development Update on Inhaled KB707 for Non-Small Cell Lung Cancer Treatment - Quiver Quantitative
Krystal Biotech Announces Update on Development Plans for Oncolo - GuruFocus
36% Response Rate: Krystal Biotech's Inhaled Cancer Drug KB707 Shows Promise in Hard-to-Treat Lung Cancer - Stock Titan
How institutional ownership impacts Krystal Biotech Inc. stockJuly 2025 Trends & Short-Term Swing Trade Alerts - Newser
Price momentum metrics for Krystal Biotech Inc. explainedMarket Activity Recap & Free Weekly Chart Analysis and Trade Guides - Newser
Krystal Biotech’s Earnings Call: Strong Growth Amid Challenges - MSN
RSI + MACD Show Convergence for Krystal Biotech Inc.July 2025 Selloffs & Daily Chart Pattern Signals - newsyoung.net
Sector ETF performance correlation with Krystal Biotech Inc.Quarterly Profit Report & AI Powered Market Entry Ideas - Newser
Using Python tools to backtest Krystal Biotech Inc. strategies2025 Winners & Losers & Low Risk Entry Point Guides - Newser
AI Trend Models Suggest Bounce for Krystal Biotech Inc.July 2025 Opening Moves & High Accuracy Investment Entry Signals - newsimpact.co.kr
Can Krystal Biotech Inc. keep up with sector leadersTrade Analysis Summary & Consistent Return Investment Signals - mustnews.co.kr
Local biotech co-founder named to Forbes 50 Over 50 - MSN
How Krystal Biotech Inc. stock performs during market volatilityGap Up & Verified Stock Trade Ideas - Newser
Krystal Biotech Inc Azioni (KRYS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):